Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rhabdomyosarcoma
What role do genetic and molecular profiling play in predicting which patients with high-risk localized RMS benefit from maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide?
Related Questions
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
What are your top takeaways in Classical Hematology from ASH 2025?
For pediatric patients with iron overload (high ferritin and transferrin saturation), do you perform HFE screening first, or proceed to non-HFE gene sequencing upfront to evaluate for HJV mutation as well?
How long do you continue to follow children with now resolved autoimmune hemolytic anemia in hematology clinic to monitor for recurrence or secondary conditions?
In pediatric Hodgkin lymphoma with symptomatic splenomegaly, what radiotherapy dose is recommended?
When would you consider genetic testing for G6PD deficiency diagnosis?
Do you recommend indefinite anticoagulation for patients with homozygous Factor V Leiden mutation who have had a provoked VTE?
How do you approach prophylactic antibiotics in patients who continue to have recurrent neutropenic fever following chemotherapy for solid tumors despite chemotherapy dose reduction and growth factor support?
How would you manage HHT with ongoing epistaxis despite IV bevacizumab, with a history of superficial thrombosis?
What is your typical surveillance imaging for a pediatric patient with history of treated sarcoma off therapy?
